Novel urinary protein biomarkerspredicting the development of microalbuminuria and renal function decline in type 1 diabetes

Diabetes Care

Volumn 35, Issue 3, 2012, Pages 549-555

  Schlatzer, Daniela ^a   Maahs, David M ^b   Chance, Mark R ^a   Dazard, Jean Eudes ^a   Li, Xiaolin ^a   Hazlett, Fred ^a   Rewers, Marian ^b   Snell Bergeon, Janet K ^b  

^a CASE WESTERN RESERVE UNIVERSITY   (United States)

^b UNIVERSITY OF COLORADO DENVER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLUSTERIN; OROSOMUCOID; PROGRANULIN; TAMM HORSFALL GLYCOPROTEIN;

ADULT; ARTICLE; CONTROLLED STUDY; DISEASE COURSE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; KIDNEY FUNCTION; MACROALBUMINURIA; MAJOR CLINICAL STUDY; MALE; MICROALBUMINURIA; PATHOGENESIS; PREDICTION; PROTEIN URINE LEVEL; PROTEOMICS; URINALYSIS;

ADULT; ALBUMINURIA; BIOLOGICAL MARKERS; CHROMATOGRAPHY, LIQUID; DIABETES MELLITUS, TYPE 1; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; KIDNEY DISEASES; MALE; MASS SPECTROMETRY; MIDDLE AGED; YOUNG ADULT;

EID: 84859024732     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc11-1491     Document Type: Article

References (42)

1. Laing SP, Swerdlow AJ, Slater SD, et al. Mortality from heart disease in a cohort of 23,000 patients with insulin-treated diabetes. Diabetologia 2003;46:760-765 (Pubitemid 36831403)
2. White NH, Sun W, Cleary PA, et al. Prolonged effect of intensive therapy on the risk of retinopathy complications in patients with type 1 diabetes mellitus: 10 years after the Diabetes Control and Complications Trial. Arch Ophthalmol 2008;126:1707-1715
3. Pambianco G, Costacou T, Orchard TJ. The prediction ofmajor outcomes of type 1 diabetes: a 12-year prospective evaluation of three separate definitions of the metabolic syndrome and their components and estimated glucose disposal rate: the Pittsburgh Epidemiology of Diabetes Complications Study experience. Diabetes Care 2007;30:1248-1254 (Pubitemid 46684655)
4. Mauer M, Zinman B, Gardiner R, et al. Renal and retinal effects of enalapril and losartan in type 1 diabetes. N Engl J Med 2009;361:40-51
5. Finne P, Reunanen A, Stenman S, Groop PH, Grönhagen-Riska C. Incidence of end-stage renal disease in patients with type 1 diabetes. JAMA 2005;294:1782-1787 (Pubitemid 41434624)
6. Edwards NL. The role of hyperuricemia and gout in kidney and cardiovascular disease. Cleve Clin J Med 2008;75(Suppl. 5):S13-S16
7. van Hecke MV, Dekker JM, Stehouwer CD, et al. EURODIAB Prospective Complications Study. Diabetic retinopathy is associated with mortality and cardiovascular disease incidence: the EURODIAB Prospective Complications Study. Diabetes Care 2005;28:1383-1389 (Pubitemid 40756701)
8. Jerums G, Panagiotopoulos S, Premaratne E, Power DA, MacIsaac RJ. Lowering ofproteinuria in response to antihypertensive therapy predicts improved renal function in late but not in early diabetic nephropathy: a pooled analysis. Am J Nephrol 2008;28:614-627 (Pubitemid 351832449)
9. Mann JF, Schmieder RE, McQueen M, et al.; ONTARGET Investigators. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet 2008;372:547-553
10. Steinke JM, Mauer M; International Diabetic Nephropathy Study Group. Lessons learned from studies of the natural history of diabetic nephropathy in young type 1 diabetic patients. Pediatr Endocrinol Rev 2008;5(Suppl. 4):958-963
11. Adachi J, Kumar C, Zhang Y, Olsen JV, Mann M. The human urinary proteome contains more than 1500 proteins, including a large proportion of membrane proteins. Genome Biol 2006;7:R80
12. Barratt J, Topham P. Urine proteomics: the present and future of measuring urinary protein components in disease. CMAJ 2007;177:361-368 (Pubitemid 47339533)
13. Perkins BA, Krolewski AS. Early nephropathy intype 1 diabetes: the importance of early renal function decline. Curr Opin Nephrol Hypertens 2009;18:233-240
14. Schlatzer DM, Dazard JE, Dharsee M, et al. Urinary protein profiles ina rat model for diabetic complications. Mol Cell Proteomics 2009;8:2145-2158
15. Wang X, Li A, Jiang Z, Feng H. Missing value estimation for DNA microarray gene expression data by Support Vector Regression imputation and orthogonal coding scheme. BMC Bioinformatics 2006;7:32
16. Dazard J-E, Hua X, Rao JS. R package MVR for joint adaptive mean-variance regularization and variance stabilization. In JSM Proceedings, Section for Statistical Programmers and Analysts. Miami Beach, FL, American Statistical Association IMS-JSM. In press
17. Hotelling H. Relations between two sets of variables. Biometrika 1936;28:321-377
18. Zou H, Hastie T. Regularization and variable selection via the elastic net. J R Statist Soc 2005;67(Series B):301-320
19. Daniel R, He Z, Carmichael KP, Halper J, Bateman A. Cellular localization of gene expression for progranulin. J Histochem Cytochem 2000;48:999-1009 (Pubitemid 30421564)
20. Vergouwe Y, Soedamah-Muthu SS, Zgibor J, et al. Progression tomicroalbuminuria in type 1 diabetes: development and validation of a prediction rule.Diabetologia 2010;53:254-262
21. Rifai N, Gillette MA, Carr SA. Protein biomarker discovery and validation: the long and uncertain path to clinical utility. Nat Biotechnol 2006;24:971-983 (Pubitemid 44215392)
22. Veenstra TD, Conrads TP, Hood BL, Avellino AM, Ellenbogen RG, Morrison RS. Biomarkers: mining the biofluid proteome. Mol Cell Proteomics 2005;4:409-418 (Pubitemid 40590561)
23. Zhao Y, Lee WN, Xiao GG. Quantitative proteomics and biomarker discovery in human cancer. Expert Rev Proteomics 2009;6:115-118
24. Coon JJ, Zürbig P, Dakna M, et al. CE-MS analysis of the human urinary proteome for biomarker discovery and disease diagnostics. Proteomics Clin Appl 2008;2:964
25. Snell-Bergeon JK, Maahs DM, Ogden LG, et al. Evaluation ofurinary biomarkers for coronary artery disease, diabetes, and diabetic kidney disease. Diabetes Technol Ther 2009;11:1-9
26. Mischak H, Delles C, Klein J, Schanstra JP. Urinary proteomics based oncapillary electrophoresis-coupledmass spectrometry in kidney disease: discovery and validation of biomarkers, and clinical application. Adv Chronic Kidney Dis 2010;17:493-506
27. Chelius D, Bondarenko PV. Quantitative profiling ofproteins in complex mixtures using liquid chromatography and mass spectrometry. J Proteome Res 2002;1:317-323 (Pubitemid 36395872)
28. Wang W, Zhou H, Lin H, et al. Quantification ofproteins and metabolites bymass spectrometry without isotopic labeling or spiked standards. Anal Chem 2003;75:4818-4826 (Pubitemid 37139783)
29. Köttgen A, Glazer NL, Dehghan A, et al. Multiple loci associated with indices of renal function and chronic kidney disease. Nat Genet 2009;41:712-717
30. Below AA, Chakraborty J, Khuder SH, Haselhuhn GD. Evaluation ofurinary Tamm-Horsfall protein in post-menopausal diabetic women. J Diabetes Complications 1999;13:204-210
31. Torffvit O, Agardh CD, Thulin T. A study ofTamm-Horsfall protein excretion in hypertensive patients and type 1 diabetic patients. Scand J Urol Nephrol 1999;33:187-191 (Pubitemid 29356220)
32. Torffvit O, Agardh CD. Tubular secretion ofTamm-Horsfall protein is decreased in type 1 (insulin-dependent) diabetic patients with diabetic nephropathy. Nephron 1993;65:227-231 (Pubitemid 23268030)
33. Chakraborty J, Below AA, Solaiman D. Tamm-Horsfall protein inpatients with kidney damage and diabetes. Urol Res 2004;32:79-83 (Pubitemid 38915394)
34. Köttgen A, Hwang SJ, Larson MG, et al. Uromodulin levels associate with a common UMOD variant and risk for incident CKD. J Am Soc Nephrol 2010;21:337-344
35. Jiang H, Guan G, Zhang R, et al. Increased urinary excretion oforosomucoid is a risk predictor of diabetic nephropathy. Nephrology (Carlton) 2009;14:332-337
36. Matheson A, Willcox MD, Flanagan J, Walsh BJ. Urinary biomarkers involved intype 2 diabetes: a review. Diabetes Metab Res Rev 2010;26:150-171
37. Uehara Y, Makino H, Seiki K, Urade Y; L-PGDS Clinical Research Group of Kidney. Urinary excretions of lipocalin-type prostaglandin D synthase predict renal injury in type-2 diabetes: a cross-sectional and prospective multicentre study. Nephrol Dial Transplant 2009;24:475-482
38. ZhouW, Guan Q, Kwan CC, et al. Loss of clusterin expression worsens renal ischemia-reperfusion injury. Am J Physiol Renal Physiol 2010;298:F568-F578
39. Trougakos IP, Gonos ES. Regulation of clusterin/apolipoprotein J, a functional homologue to the small heat shock proteins, by oxidative stress in ageing and age-related diseases. Free Radic Res 2006;40:1324-1334 (Pubitemid 44698281)
40. Rosenberg ME, Girton R, Finkel D, et al. Apolipoprotein J/clusterin prevents aprogressive glomerulopathy of aging. Mol Cell Biol 2002;22:1893-1902 (Pubitemid 34175004)
41. He Z, Bateman A. Progranulin (granulin-epithelin precursor, PC-cell-derived growth factor, acrogranin) mediates tissue repair and tumorigenesis. J Mol Med (Berl) 2003;81:600-612 (Pubitemid 37357675)
42. Kojima Y, Ono K, Inoue K, et al. Progranulin expression inadvanced human atherosclerotic plaque. Atherosclerosis 2009;206:102-108